



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TO/SB/08b (08-03)
Approved for use through 06/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/644,797
		Filing Date	December 17, 2003
		First Named Inventor	Katherine Meyer Siegler
		Art Unit	1643
		Examiner Name	Stephen L. Rawlings
Attorney Docket Number	111828-00109		
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR		MICHAEL, Anja et al, "Serum Macrophage Migration Inhibitory Factor Is Not Elevated in Patients with Prostate Cancer". Cancer Epidemiology, Biomarkers & Prevention, Vol. 13, pages 328-329, February 2004.	
		LI, Haojie et al, "Prediagnostic Plasma Vascular Endothelial Growth Factor Levels and Risk of Prostate Cancer". Cancer Epidemiology, Biomarkers & Prevention, June 2005 Vol. 14(6), pages 1557-1561.	
		YOUSEF, G. M. et al, "Differential Expression of the Human Kallikrein Gene 14 (KLK14) in Normal and Cancerous Prostatic Issues". Prostate, September 1, 2003 Vol. 56(4), pages 287-292.	
		BORGONO, Carla A. "Human Kallikrein 14: A New Potential Biomarker for Ovarian and Breast Cancer". Cancer Research Vol. 63, December 15, 2003, pages 9032-9041.	

Examiner Signature		Date Considered	7/13/07
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.